What is Absci?
Headquartered in Vancouver, Washington, Absci operates at the intersection of synthetic biology and pharmaceutical innovation. The company specializes in the development of protein-based drugs and utilizes engineered E. coli to streamline the production of complex proteins and antibodies. By leveraging its proprietary platform, Absci aims to unlock the potential of biologics, significantly reducing the time and cost associated with drug discovery. Its market position is defined by its ability to bridge the gap between computational design and biological manufacturing, providing a scalable solution for the biopharmaceutical industry's most pressing challenges.
How much funding has Absci raised?
Absci has raised a total of $286.9M across 7 funding rounds:
Series A
$5.1M
Series C
$12M
Multiple Rounds
$80.8M
Other Financing Round
$125M
Other Financing Round
$64M
Series A (2016): $5.1M with participation from Phoenix Venture Partners and Oregon Venture Fund
Series C (2018): $12M led by Greenbridge Partners, Oregon Venture Fund, and Phoenix Venture Partners
Series D (2020): $15.4M supported by JSR Life Sciences, KBI Biopharma, Phoenix Venture Partners, Columbia Ventures Corporation, Oregon Venture Fund, and Washington Research Foundation
Debt (2020): $350K featuring PPP
Series E (2020): $65M backed by Casdin Capital
Other Financing Round (2021): $125M with participation from Redmile Group , LLC and Casdin Capital , LLC
Other Financing Round (2025): $64M, investors not publicly disclosed
Key Investors in Absci
Phoenix Venture Partners
PVP is a venture capital firm that specializes in transforming innovative technologies into market-ready products, focusing on advanced materials and life sciences.
Oregon Venture Fund
Oregon Venture Fund is dedicated to investing in and supporting the next generation of world-class growth companies, focusing on ambitious founding teams with innovative solutions.
Casdin Capital
Casdin Capital brings deep expertise and a long-term perspective to financing the next generation of life science innovation, particularly in diagnostics and molecular information.
What's next for Absci?
With the recent influx of capital, Absci is well-positioned to accelerate its pipeline development and expand its technological capabilities. The company is expected to focus on deepening its strategic partnerships and enhancing its manufacturing infrastructure to meet the growing demand for high-quality biologics. As the firm transitions into its next phase of growth, the focus will likely shift toward clinical validation and the commercialization of its lead candidates. By maintaining a robust balance sheet, Absci is prepared to navigate the complexities of the biotech market while continuing to push the boundaries of protein engineering and therapeutic discovery.
See full Absci company page
